|
David C Rubinsztein, M.B. Ch.B; B.Sc. (Med) Hons; Ph.D.,
FRCPath, FMedSci, FRS, is a UK Dementia Research Institute Professor,
Professor of Molecular Neurogenetics at the University of Cambridge,
Deputy Director of the Cambridge Institute for Medical Research and
Academic Lead of the Alzheimer¡¯s Research Cambridge Drug Discovery
Institute. He has been a leader in the field of autophagy, particularly
in the context of neurodegenerative diseases. His laboratory pioneered
the strategy of autophagy upregulation as a possible therapeutic approach
in various neurodegenerative diseases and has identified drugs and novel
pathways that may be exploited for this objective. He has made key
contributions to illuminating the relevance of autophagy defects as a
disease mechanism and to the basic cell biology of this important
catabolic process. His laboratory has also identified druggable pathways
independent of autophagy that may be relevant to diseases caused by
aggregate-prone proteins. These insights into a fundamental catabolic
process open novel avenues for developing potential therapies. Dr.
Rubinsztein has been elected as a Fellow of the Royal Society, Fellow of
the Academy of Medical Sciences, and as an EMBO member. He was awarded
the Graham Bull Prize for Clinical Science (Royal College of Physicians),
the Thudichum Medal (Biochemical Society) and the Roger the Spoelberch
Prize for his contributions.
|
